Neurocrine Biosciences, Inc. discovers and develops treatments for patients with neurological, endocrine, and psychiatric disorders.
High growth potential with proven track record.
Share Price & News
How has Neurocrine Biosciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NB3 has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: NB3 exceeded the German Biotechs industry which returned 7.2% over the past year.
Return vs Market: NB3 exceeded the German Market which returned 14.1% over the past year.
Price Volatility Vs. Market
How volatile is Neurocrine Biosciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Neurocrine Biosciences undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NB3 (€95.8) is trading below our estimate of fair value (€191.82)
Significantly Below Fair Value: NB3 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NB3 is poor value based on its PE Ratio (259.3x) compared to the Biotechs industry average (43.8x).
PE vs Market: NB3 is poor value based on its PE Ratio (259.3x) compared to the German market (20.9x).
Price to Earnings Growth Ratio
PEG Ratio: NB3 is poor value based on its PEG Ratio (7.5x)
Price to Book Ratio
PB vs Industry: NB3 is overvalued based on its PB Ratio (15.2x) compared to the DE Biotechs industry average (3.5x).
How is Neurocrine Biosciences forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NB3's forecast earnings growth (34.8% per year) is above the savings rate (-0.4%).
Earnings vs Market: NB3's earnings (34.8% per year) are forecast to grow faster than the German market (13.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: NB3's revenue (19.4% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: NB3's revenue (19.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NB3's Return on Equity is forecast to be high in 3 years time (34.9%)
How has Neurocrine Biosciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NB3 has a large one-off loss of $167.3M impacting its December 31 2019 financial results.
Growing Profit Margin: NB3's current net profit margins (4.7%) are higher than last year (4.7%).
Past Earnings Growth Analysis
Earnings Trend: NB3 has become profitable over the past 5 years, growing earnings by 23.7% per year.
Accelerating Growth: NB3's earnings growth over the past year (75.3%) exceeds its 5-year average (23.7% per year).
Earnings vs Industry: NB3 earnings growth over the past year (75.3%) exceeded the Biotechs industry -4.7%.
Return on Equity
High ROE: NB3's Return on Equity (5.8%) is considered low.
Return on Assets
Return on Capital Employed
How is Neurocrine Biosciences's financial position?
Financial Position Analysis
Short Term Liabilities: NB3's short term assets ($831.0M) exceed its short term liabilities ($565.3M).
Long Term Liabilities: NB3's short term assets ($831.0M) exceed its long term liabilities ($103.8M).
Debt to Equity History and Analysis
Debt Level: NB3's debt to equity ratio (64.2%) is considered high.
Reducing Debt: Insufficient data to determine if NB3's debt to equity ratio has reduced over the past 5 years.
Inventory Level: NB3 has a low level of unsold assets or inventory.
Debt Coverage by Assets: NB3's debt is covered by short term assets (assets are 2x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NB3 is profitable, therefore cash runway is not a concern.
Forecast Cash Runway: NB3 is profitable, therefore cash runway is not a concern.
What is Neurocrine Biosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NB3's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate NB3's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NB3's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NB3's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NB3's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kevin Gorman (61yo)
Dr. Kevin C. Gorman, Ph.D., has been the President and Chief Executive Officer of Neurocrine Biosciences, Inc. since January 2008. Dr. Gorman is a Founder of Neurocrine Biosciences, Inc. Dr. Gorman served ...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD8.63M) is above average for companies of similar size in the German market ($USD4.36M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
|CEO & Director||12.1yrs||US$8.63m||0.47% $42.0m|
|Chief Financial Officer||2.3yrs||US$2.69m||0.0062% $553.4k|
|Chief Business Development and Strategy Officer||9.1yrs||US$4.57m||0.10% $8.9m|
|Chief Commercial Officer||4.8yrs||US$3.67m||0.022% $1.9m|
|Chief Medical Officer||2.1yrs||US$8.31m||0.0081% $722.7k|
|Chief Research Officer||13.1yrs||US$3.33m||0.12% $10.8m|
|Head of Investor Relations||0yrs||no data||no data|
|Chief Legal Officer & Corporate Secretary||5.3yrs||no data||0.026% $2.3m|
|Chief Human Resources Officer||2.4yrs||no data||0.0050% $450.4k|
|Chief Development Officer||13.2yrs||US$2.97m||0.16% $14.2m|
Experienced Management: NB3's management team is seasoned and experienced (5.3 years average tenure).
|CEO & Director||12.1yrs||US$8.63m||0.47% $42.0m|
|Independent Director||21.8yrs||US$737.25k||0.032% $2.9m|
|Independent Director||20.8yrs||US$732.58k||0.052% $4.6m|
|Independent Chairman of the Board||8.8yrs||US$873.80k||0.027% $2.4m|
|Independent Director||27yrs||US$712.75k||0.24% $21.9m|
|Independent Director||4.3yrs||US$730.25k||no data|
|Director||0yrs||no data||no data|
|Director||0.4yrs||no data||no data|
|Independent Director||4.4yrs||US$733.25k||no data|
Experienced Board: NB3's board of directors are seasoned and experienced ( 10.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Neurocrine Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Neurocrine Biosciences, Inc.
- Ticker: NB3
- Exchange: DB
- Founded: 1992
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$9.668b
- Listing Market Cap: US$8.955b
- Shares outstanding: 92.29m
- Website: https://www.neurocrine.com
Number of Employees
- Neurocrine Biosciences, Inc.
- 12780 El Camino Real
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NBIX||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||May 1996|
|NB3||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 1996|
|0K6R||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||May 1996|
Neurocrine Biosciences, Inc. discovers and develops treatments for patients with neurological, endocrine, and psychiatric disorders. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of adults with tardive dyskinesia; and ORILISSA (elagolix) for the management of moderate to severe endometriosis pain in women in the United States. It also develops opicapone, a catechol-o-methyltransferase inhibitor, for the treatment of Parkinson’s disease patients; crinecerfont for the treatment of congenital adrenal hyperplasia; and NBIb-1817, an investigational gene therapy for the treatment of Parkinson’s disease. In addition, the company is developing NBI-921352, an inhibitor being developed to treat pediatric patients with SCN8A-DEE and other potential indications, including adult focal epilepsy; and ACT-709478, an orally active and brain penetrating T-type calcium channel blocker for potential use in certain forms of generalized epilepsy. Neurocrine Biosciences, Inc. has collaboration agreements with AbbVie Inc.; Mitsubishi Tanabe Pharma Corporation; BIAL – Portela & Ca, S.A.; Jnana Therapeutics Inc.; Voyager Therapeutics, Inc.; and Xenon Pharmaceuticals Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/19 20:38|
|End of Day Share Price||2020/02/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.